Cardionovum

Be up
to date.

Latest press release

Globally first patient treated with LEGFLOW 018 in MOL, Belgium

Dr. Berghmans and Dr. van Bouckenooghe were the worldwide first users of the LEGFLOW 018 on a Patient with CLI disease. The product was used in BtK and showed excellent performance. In addition the patient received a DCB therapy with our LEGFLOW OTW in the SFA as well.

Learn more >>

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

CARDIONOVUM GmbH today announced the completion of enrollment of the RAPID trial. Results will be used to further support the safety and effectiveness of CARDIONOVUM’s Legflow® drug-coated balloon (DCB).

Learn more >>

Cardionovum announces enrollment of first patient in MAGNIFICENT trial

CARDIONOVUM GmbH, a medical technology company developing and commercializing innovative medical devices such as drug-coated balloons and drug-eluting stents for the treatment of coronary and peripheral artery disease, announced today the enrollment of the first patient in the MAGNIFICENT trial.

Learn more >>

RESTORE clinical study results on in-stent restenosis.

Cardionovum experiences increase in demand for its innovative, and next generation „RESTORE Paclitaxel-releasing coronary balloon dilatation catheter.“ The American Journal of Cardiology, issue December 2015, published study results on the efficacy and safety of Paclitaxel coated balloon catheters for the treatment of in-stent restenosis in high risk patients. The RESTORE DEB showed significant superiority with lowest incidence of restenosis, if compared to other contemporary coronary DEBs.

Learn more >>

Cardionovum at LINC 2016

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial.

Learn more >>

Early APERTO patient results look promising.

Cardionovum prepares for a first international publication on 6-12 months FU patient results from the ongoing APERTO clinical study program. The APERTO Paclitaxel-releasing high pressure shunt balloon dilatation catheter was exclusively designed to treat shunt stenosis of hemodialysis patients.

Learn more >>

Upcoming events

Cardionovum® at GISE 2025

Cardionovum® is pleased to invite you to visit us at booth #51.

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

Date: Oct 01, 2025–Oct 04, 2025

Latest events

Cardionovum® at VAS 2023

Cardionovum® is pleased to invite you to visit us at our booth located in the Plenary hall: Exhibition area – A (2nd floor)

Location:

Centro de Congressos da Alfândega do Porto
Rua Nova da Alfândega, 4050-430
Porto, Portugal

Date: Apr 27, 2023–Apr 30, 2023

Cardionovum® at Deutschen Gesellschaft für Kardiologie (DGK) 2023

Cardionovum® is glad to invite you to visit us at booth #017

Location:

Congress Center Rosengarten Mannheim (CCR)
Rosengartenplatz 2, 68161
Mannheim, Germany

Date: Apr 12, 2023–Apr 16, 2023

Cardionovum® is glad to invite you to attend the scientific session:

Clinical Scenario: DES, BRS & DCB - New Insights

  • Dott. Keeble will disclose his presentation entitled “DCB-alone PCI in De Novo Lesions: Exploring New Frontiers with RESTORE® DCB”

    Monday 5th December at 09:15h
    Hall H

Location:

David Intercontinental Convention Center
12 Kaufman St,
Tel Aviv, 61501 Israel

Date: Dec 05, 2022–Dec 06, 2022

Learn more >>

go top